

2020 Vision

- 563** What contributes to quality of life in Parkinson's disease: a re-evaluation
A Schrag, N Quinn

- 566** Too much of a good thing: hedonistic homeostatic dysregulation and other behavioural consequences of excessive dopamine replacement therapy in Parkinson's disease
J D O'Sullivan

Editorial commentaries

- 568** Neurology in the time of COVID-19
H Manji, A S Carr, W J Brownlee, M P Lunn

- 571** Remember the null hypothesis?
C Randolph

Autonomic

- 572** New insights in post-traumatic headache with cluster headache phenotype: a cohort study
L Grangeon, E O'Connor, C-K Chan, L Akijian, T M Pham Ngoc, M S Matharu

Cerebrovascular disease

- 580** Ten-year risks of recurrent stroke, disability, dementia and cost in relation to site of primary intracerebral haemorrhage: population-based study
L Li, R Luengo-Fernandez, S M Zuurbier, N C Beddows, P Lavalley, L E Silver, W Kuker, P M Rothwell

Cognitive neurology

- 586** Clinical and neuropsychological profile of patients with dementia and chronic traumatic encephalopathy
C LoBue, J Schaffert, C M Cullum, M E Peters, N Didehban, J Hart, C L White

Migraine

- 593** Migraine and risk of stroke
L R Øie, T Kurth, S Gulati, D W Dodick

Neuro-inflammation

- 605** CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD
I Kleerekoper, M K Herbert, H B Kuiperij, D K Sato, K Fujihara, D Callegaro, R Marignier, A Saiz, M Senel, H Tumani, B A De Jong, S A Trip, I Nakashima, M M Verbeek, A Petzold

Neurodegeneration

- 612** Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia
E L van der Ende, M Xiao, D Xu, J M Poos, J L Panman, L C Jiskoot, L H Meeter, E GP Dopfer, J M Papma, C Heller, R Convery, K Moore, M Bocchetta, M Neason, G Peakman, D M Cash, C E Teunissen, C Graff, M Synofzik, F Moreno, E Finger, R Sánchez-Valle, R Vandenberghe, R Laforce Jr, M Masellis, M C Tartaglia, J B Rowe, C R Butler, S Ducharme, A Gerhard, A Daneke, J Levin, Y AL Pijnenburg, M Otto, B Borroni, F Tagliavini, A de Mendonca, I Santana, D Galimberti, H Seelaar, J D Rohrer, P F Worley, J C van Swieten, on behalf of the Genetic Frontotemporal Dementia Initiative (GENFI)

- 622** Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington's disease (Enroll-HD)
K L Harris, W-L Kuan, S L Mason, R A Barker

[MORE CONTENTS ►](#)

Editor

Matthew C Kiernan (Australia)

Deputy Editors

Karen L Furie (USA)

Satoshi Kuwabara (Japan)

Lawrence Wong (China)

Associate Editors

Alan Carson (UK)

Nick Ward (UK)

Peter Warnke (USA)

Commissioning Editor

Martin Turner (UK)

Web Editors

Clare Caldwell

Arun Krishnan

Cindy Lin

Steve Vucic

Podcast Editor

Colin Mahoney

JNNP Blog Editors

Jose Manuel Matamala

Thanuja Dharmadasa

JNNP Facebook Editors

Cindy Lin

William Huynh

Editors, Practical Neurology

Geraint Fuller (UK)

Phil Smith (UK)

Editorial Office

Journal of Neurology Neurosurgery & Psychiatry

BMJ Publishing Group Ltd

BMA House

Tavistock Square

London WC1H 9JR, UK

E: jnnp@bmj.com

Twitter: [@JNNP_BMJ](https://twitter.com/JNNP_BMJ)

ISSN: 0022-3050 (print)

ISSN: 1468-330X (online)

Impact factor: 8.327

Disclaimer: The Editor of JNNP has been granted editorial freedom and JNNP is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. JNNP is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by JNNP does not imply endorsement. BMJ Publishing Group Limited shall not be liable for any loss, injury or damage howsoever arising from JNNP (except for liability which cannot be legally excluded).

Copyright: © 2020 BMJ Publishing Group Ltd. All rights reserved; no part of this publication may be reproduced in any form without permission.

JNNP is published by BMJ Publishing Group Ltd, typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper from sustainable forests.

Journal of Neurology Neurosurgery & Psychiatry (ISSN No: 0022-3050) is distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431. POSTMASTER: send address changes to *Journal of Neurology Neurosurgery & Psychiatry*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA



EDITOR'S CHOICE



PATIENT'S CHOICE



OPEN ACCESS



IMPACT COMMENTARIES



MEMBER SINCE 2008



COMMITTEE ON PUBLICATION ETHICS



RECYCLE



MCQs

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been chosen in conjunction with the BMJ Patient Forum to be of particular interest to patients and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme. See <http://authors.bmj.com/open-access/>

The article is part of the Impact Commentaries series

C O P E

Member since 2008

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>

When you have finished with this magazine please recycle it.

The online version of this article contains multiple choice questions hosted on BMJ Learning.

- 631** Distinct dopaminergic abnormalities in traumatic brain injury and Parkinson's disease
P O Jenkins, A-A Roussakis, S De Simoni, N Bourke, J Fleminger, J Cole, P Piccini, D Sharp


Neuropsychiatry

- 638** Outcome measurement in functional neurological disorder: a systematic review and recommendations
 
S Pick, D G Anderson, A A Asadi-Pooya, S Aybek, G Baslet, B R Bloem, A Bradley-Westguard, R J Brown, A J Carson, T Chalder, M Damianova, A S David, M J Edwards, S A Epstein, A J Espay, B Garcin, L H Goldstein, M Hallett, J Jankovic, E M Joyce, R A Kanaan, R C Keynejad, K Kozłowska, K LaFaver, W C LaFrance, Jr., A E Lang, A Lehn, S Lidstone, C W Maurer, B Milton, F Morgante, L Myers, C Nicholson, G Nielsen, D L Perez, S Popkirov, M Reuber, K S Rommelfanger, P Schwingenshuh, T Serranova, P Shotbolt, G T Stebbins, J Stone, M A J Tijssen, M Tinazzi, T R Nicholson

Neuromuscular

- 650** Ultrastructural mechanisms of macrophage-induced demyelination in Guillain-Barré syndrome
H Koike, Y Fukami, R Nishi, Y Kawagashira, M Iijima, M Katsuno, G Sobue

Multiple sclerosis

- 660** Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)

H Butzkueven, L Kappos, H Wiendl, M Trojano, T Spelman, I Chang, R Kasliwal, S Jaitly, N Campbell, P-R Ho, S Licata, On behalf of the Tysabri Observational Program (TOP) Investigators

Postscript

- 669** Letters
